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AbstrACt
Introduction In adults, muscle disease (MD) is often 
a chronic long-term condition with no definitive cure. It 
causes wasting and weakness of the muscles resulting 
in a progressive decline in mobility, alongside other 
symptoms, and is typically associated with reduced 
quality of life (QoL). Previous research suggests that a 
psychological intervention, and in particular Acceptance 
and Commitment Therapy (ACT), may help improve QoL 
in MD. ACT is a newer type of cognitive behavioural 
treatment that aims to improve QoL by virtue of 
improvement in a process called psychological flexibility. 
The primary aim of this randomised controlled trial (RCT) 
is to evaluate the efficacy of a guided self-help ACT 
programme for improving QoL in people with MD. Main 
secondary outcomes are mood, symptom impact, work 
and social adjustment and function at 9-week follow-up.
Methods and analysis Acceptance and Commitment 
Therapy for Muscle Disease is an assessor-blind, 
multicentre, two-armed, parallel-group RCT to assess 
the efficacy of ACT plus standard medical care (SMC) 
compared with SMC alone. Individuals with a diagnosis 
of one of four specific MDs, with a duration of at least 6 
months and with mild to moderate anxiety or depression 
(Hospital Anxiety and Depression Scale score ≥8) will 
be recruited from UK-based MD clinics and MD patient 
support organisations. Participants will be randomised 
to either ACT plus SMC or SMC alone by an independent 
randomisation service. Participants will be followed up 
at 3, 6 and 9 weeks. Analysis will be intention to treat, 
conducted by the trial statistician who will be blinded to 
treatment allocation.
Ethics and dissemination The study has received full 
ethical approval. Study results will be disseminated via 
peer-reviewed publications, conference presentations and 
journal articles. Data obtained from the trial will enable 
clinicians and health service providers to make informed 
decisions regarding the efficacy of ACT for improving QoL 
for patients with MD.
trial registration number NCT02810028.
Protocol version V.11 (4 April 2017).
IntroduCtIon  
background and rationale
Muscle diseases (MDs) are a group of primary 
disorders of the muscle, the majority of which 
are chronic and progressive. They affect 
approximately over 70 000 people (chil-
dren and adults) in the UK.1 The diagnosis 
of a specific MD is based on several criteria 
including the pattern of the muscle weakness, 
the muscle biopsy appearances and in some 
cases genetic testing. Four MDs, namely limb 
girdle muscular dystrophy (LGMD), Beck-
er’s muscular dystrophy (BMD) (dystrophin 
deficiency), facioscapulohumeral muscular 
dystrophy (FSHD) and inclusion body 
strengths and limitations of this study
 ► Acceptance and Commitment Therapy for Muscle 
Disease is the first randomised controlled trial to 
test the efficacy of an Acceptance and Commitment 
Therapy-informed intervention for muscle diseases 
(MDs) against standard medical care (SMC).
 ► To our knowledge, this is the largest trial of a psy-
chological intervention for MD that primarily targets 
quality of life.
 ► In order to improve access and increase uptake, the 
intervention is brief and designed to be delivered re-
motely (via email and telephone).
 ► Only a short follow-up period was included, and con-
sequently, this study will not be able to investigate 
longer-term treatment effects. An intrinsic limitation 
to the study is the lack of comparable therapist’s 
time and attention within the SMC alone group.
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myositis (IBM), comprise a significant proportion of 
those seen in an adult muscle clinic. They are character-
ised by progressive limb muscle wasting and weakness that 
cause difficulties with mobility and physical functioning. 
Some MDs also involve bulbar muscles causing dysphagia, 
respiratory muscles causing respiratory compromise and 
cardiac muscle causing cardiac symptoms. As well as weak-
ness, commonly reported symptoms include chronic pain, 
sleep disturbance and fatigue.2 3 Unlike some MDs, these 
four MDs do not have additional multisystem or central 
nervous system involvement. At present, most MDs are 
without disease-modifying treatments or cures.
Typically, people with MD report reduced quality of life 
(QoL) and may experience increased levels of anxiety 
and depression.4 5 A systematic review of 26 studies high-
lighted that, compared with controls, people with MD 
had compromised QoL in all areas of functioning.5 The 
degree of physical disability is a determinant of QoL in 
MDs.5 Therefore, clinical treatment is often directed at 
maintaining physical functioning. For example, phys-
iotherapy and occupational therapy are applied to 
maximise remaining muscle function, and patients are 
monitored for any cardiac or respiratory problems that 
may need supportive treatment.
However, physical disability does not explain all the 
variance in QoL.4 6 7 Psychological variables such as illness 
beliefs,6 8 coping methods9–11 and psychological flexi-
bility12 have been shown to account for variance in QoL. 
These findings are in line with a biopsychosocial model13 
where QoL is theorised to depend on the interaction of 
psychological factors with biological and social factors.
The relationship between QoL and psychosocial factors 
in MD provides a treatment opportunity. In the absence 
of a direct cure for MD, psychological interventions may 
offer a way to enhance QoL. Encouragingly, a recent 
small randomised controlled trial (RCT) of a traditional 
cognitive behavioural intervention for improving fatigue 
in FSHD showed a beneficial effect on fatigue and QoL.14
Acceptance and Commitment therapy
Dependent on treatment aims, several types of psycholog-
ical interventions may be helpful for people with MD.15 
Acceptance and Commitment Therapy (ACT) is a newer 
form of cognitive-behavioural approach that focuses on 
improving a process called psychological flexibility.16 
Psychological flexibility is “[…] the capacity to persist or 
to change behaviour in a way that includes conscious and 
open contact with thoughts and feelings, appreciates what 
the situation affords, and serves one’s goals and values”.17 
In observational studies, psychological flexibility has been 
shown to be predictive of positive outcomes (QoL and 
mood) and better functioning across a range of chal-
lenging contexts, such as living with chronic illness and 
chronic pain. A 4-month prospective observational study 
with a group of people with MD observed that psycholog-
ical flexibility was predictive of change in life satisfaction 
and anxiety.18
Given its focus on improving psychological flexibility, 
ACT may prove beneficial for those with MD. In ACT, 
a number of treatment techniques are used to improve 
psychological flexibility including therapist interaction, 
mindfulness and functional analysis. These aim to: (1) 
help individuals become more aware of thoughts and 
feelings and their relationship to, in this case, their MD; 
(2) broaden the range of behaviours (often to include 
open and willing responses) that can be applied when in 
the presence of difficult thoughts and feelings and (3) 
help them to flexibly choose those behaviours that help 
them to make progress on their overarching goals and 
values.
Several recent meta-analyses have suggested that ACT 
is an efficacious treatment for improving mood and QoL 
in mental health conditions19 20 and chronic pain.21 In 
chronic diseases, there is a growing evidence base,12 with 
encouraging results for trials with cancer,22 diabetes23 and 
epilepsy24 populations. However, to date, most studies 
of ACT for chronic diseases have been of a preliminary 
nature (ie, small, uncontrolled and/or lower quality).12 
Thus, an adequately powered, rigorous evaluation of ACT 
for improving QoL in chronic diseases will be a helpful 
addition to the literature.
the selection of a guided self-help approach
The one comprehensive trial of a psychological interven-
tion in MD14 tested the efficacy of a 16-session traditional 
cognitive behavioural therapy for improving fatigue. 
While results were encouraging, on both fatigue and 
secondary outcomes such as QoL and mood, for several 
reasons (including the time spent travelling), uptake was 
low, and a proportion (24%) struggled to achieve even 
a minimal level of adherence to the intervention. This 
suggests that issues, perhaps mobility difficulties and treat-
ment length, may hinder face-to-face treatment options 
for many with MD. A further problem with the develop-
ment and implementation of any new treatment concerns 
the resource limitations common to many health service 
providers, including the National Health Service (NHS) 
in the UK.
A practical solution to this problem could be the imple-
mentation of an intervention delivered remotely through 
online and computerised self-guided resources aided by 
telephone or video calls. Such methods of delivery are 
increasingly feasible given that the majority of UK house-
holds now have web access. In addition, recent systematic 
reviews suggest that promising results can be obtained 
from web-based interventions for adults with chronic 
illnesses and depression.25–27 Web-based interventions 
not only remove the burden of travel but also allow the 
completion of material at a convenient place, time and 
pace. Remotely delivered interventions can be a cost-ef-
fective approach for providing treatment, increasing its 
chances of wider implementation.
Given the potential benefits of using ACT within an MD 
population and taking into account potential barriers to 
participation, we developed, for this population, a brief 
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self-guided intervention that can be supported remotely 
via email and telephone contact with a therapist. We 
assessed this in a preliminary multiple-baseline case 
series with seven participants.28 The results of this case 
series suggested that such an approach was practicable 
and acceptable, and that mood and QoL might respond 
to this treatment. Given this promising evaluation, we 
plan to conduct an RCT, to evaluate the efficacy of this 
intervention for improving QoL in people living with 
MD.
This protocol describes a multicentre, two-armed, 
parallel-group RCT to assess the efficacy of self-guided 
ACT in improving QoL in individuals with MDs. A total of 
154 people referred from MD clinics, Muscular Dystrophy 
UK (MD-UK) and specific MD registries will be randomly 
allocated to receive either self-guided ACT plus standard 
medical care (SMC) or SMC alone. We hypothesise that 
the group who receive self-guided ACT plus SMC will 
report an improved QoL at the primary endpoint of 9 
weeks follow-up compared with those receiving SMC 
alone.
objectives
Primary objective
The primary objective is to evaluate the efficacy of ACT 
plus SMC on QoL compared with SMC alone at 9 weeks.
Secondary objectives
1. To evaluate the impact of ACT plus SMC compared 
with SMC alone on secondary outcomes: mood, symp-
tom impact domains, work and social adjustment and 
function at 9-week follow-up;
2. To assess the processes that may be responsible for me-
diating the treatment effect;
3. To evaluate participants’ views of the intervention and 
factors that act as facilitators and barriers to participa-
tion via a nested qualitative study.
trial design
Acceptance and Commitment Therapy for Muscle 
Disease is an assessor-blind, multicentre, two-armed, 
parallel-group RCT.
MEthods: PArtICIPAnts, IntErvEntIons And outCoMEs
setting
A total of 154 participants will be recruited from UK NHS 
MD clinics, MD-UK and three disease-specific registries 
(FSHD, dysferlin and IBM). After obtaining consent, the 
baseline assessments will take place in MD clinics at King’s 
College Hospital (NHS Foundation Hospital Trust), the 
Royal London Hospital (Barts Health NHS Trust) and 
University Hospital Southampton (NHS Foundation 
Trust). The remainder of the study including treatment 
will be conducted remotely via email, telephone or video 
calls.
Eligibility criteria
Inclusion criteria
1. Adults (aged 18 years and over) diagnosed with one 
of the following MDs that has been present for greater 
than 6 months:
2. one of the limb girdle muscular dystrophies LGMDs 
genetically or biopsy proven,
3. Becker's muscular dystrophy (BMD (dystrophin defi-
ciency) with biopsy or genetic diagnosis,
4. Facioscapulohumeral muscular dystrophy (FSHD) di-
agnosed clinically with specific genetic abnormality in 
the subject or their family,
5. Inclusion body myositis (IBM) clinic-pathologically 
defined, clinically defined or probable IBM based on 
European Neuromuscular Centre research diagnostic 
criteria 2013,29
6. Potential participants must have access to the internet 
and a computer to receive the study materials;
7. Hospital Anxiety and Depression Scale (HADS) score 
of ≥8 for depression or ≥8 for anxiety.
Exclusion criteria
1. Unstable complications of MDs including neuromus-
cular respiratory weakness or ’cardiomyopathy,
2. Major active comorbidities unrelated to MD (such as 
arthritis, respiratory disease, cardiovascular disease),
3. Current diagnosis of an active major mental health dis-
order likely to interfere with participation,
4. Current or recent participation in other treatment in-
tervention studies (<4 weeks after completion),
5. Currently receiving psychological support or psycho-
therapy,
6. Inability to read English questionnaires,
7. Cognitive impairment that would prevent compre-
hension of ACT modules and questionnaires (as as-
sessed by the Montreal Cognitive Assessment 5 min 
protocol30).
IntErvEntIons
Acceptance and Commitment therapy
The intervention is a remotely supported, guided self-
help ACT programme (developed mainly by CDG and 
LM, informed by other sources).16 22 31 It consists of four 
modules and corresponding audio files supported by 
five telephone support sessions with the trial therapist 
(table 1). The first three modules are expected to take 
the participant 1 hour 30 min each, and the final module 
45 min to complete. This includes time to read the 
modules, listen to the audio files and work through tasks 
and exercises. During the first call, prior to receiving 
the first module (by either telephone or video call), the 
therapist will provide a 15-minute introduction then 
email the first module. The subsequent three phone 
calls will each last 30 min and will be followed by the 
next module. The telephone sessions provide partici-
pants with a chance to discuss the modules they have 
read, including their experiences of the exercises, and 
 o
n
 22 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022083 on 3 October 2018. Downloaded from 
4 Rose MR, et al. BMJ Open 2018;8:e022083. doi:10.1136/bmjopen-2018-022083
Open access 
receive help with difficulties encountered. A 15-minute 
phone call will follow the final module to conclude the 
treatment.
The clinical psychologist delivering the ACT support 
sessions will attend a 3-day training session prior to the 
start of recruitment. The first day will cover the rationale 
behind the study and insights into MD diagnosis, symp-
toms and impact on QoL (led by MR, a consultant neurol-
ogist). Details of the study protocol will be reviewed as 
well as the role of the therapist, standard operating proce-
dures, recording and storage of the support sessions 
and confidential information, deviations, drop-outs and 
adverse event procedures (led by TC, professor of cogni-
tive behavioural therapy). The ACT training including 
presentations, exercises and role plays will last 2 days. 
This will be led by LM, a clinical psychologist and expert 
in ACT, assisted by CDG, an ACT-trained clinical psychol-
ogist. Obstacles to patient engagement with ACT as well 
as the difficulties of delivering the sessions remotely and 
within a brief time frame will be discussed. The therapist 
will attend monthly supervision meetings with a clinical 
supervisor (LM) to develop their skills and to ensure 
therapy fidelity and adherence to trial protocol. The ther-
apist’s treatment competence will be periodically assessed 
with an ACT fidelity scale. This will inform monthly super-
vision sessions between therapist and clinical supervisor 
throughout the trial.
treatment fidelity
All ACT support sessions will be audio-recorded to assess 
treatment fidelity. At the end of the trial, a random sample 
of recordings will be analysed for overall fidelity by two 
independent researchers. A fidelity measure is currently 
being developed by CDG and LM. This comprises a 
basic therapeutic competence scale and an ACT-specific 
fidelity scale informed by guidelines provided by Plumb 
and Vilardaga.32
standard medical care
All participants will receive SMC, which involves the 
continuation of any current medical practices (without 
any psychological therapy). SMC would be (1) review of 
functional impairment arising from their muscle weak-
ness and measures suggested to ameliorate the resulting 
disability with home adaptations and assistive devices, (2) 
monitoring for respiratory or cardiac complications and 
appropriate referral for their management if required, 
(3) recommendations for local physiotherapy, (4) recom-
mendations for falls management where appropriate and 
(5) answering queries about their condition usually 
using information leaflets from the national organisation 
MD-UK or from disease support groups.
baseline measures
Participants will complete baseline questionnaires (see 
table 2) at the MD clinics with the research assistant 
Table 1 Summary of ACT modules
Module 1: mindfulness 
and unhooking
 ► Normalising difficult thoughts and feelings, given the context of MD, and associated struggles.
 ► Discussion of consequences from trying to get rid of unwanted thoughts and feelings and 
opportunities for alternative responses.
1. Introducing other ways to interact with unwanted thoughts and feelings:Mindfulness or learning 
to be present in the moment and experience thoughts and feelings in a non-judgemental way.
2. Unhooking from thoughts or learning ways to step-back from thoughts that often restrict actions 
or lead to avoidance.
 ► Homework 1: daily diary of mindfulness practice.
 ► Homework 2: identifying where one struggles and experimenting with other responses.
Module 2: follow your 
values
 ► Identifying values and ways to pursue them with MD. Exploring the link between difficult thoughts 
and feelings and one’s goals and values.
 ► Homework 1: continuation of daily mindfulness practice
 ► Homework 2: setting goals in the context of values, experimenting with taking the ‘smallest 
possible step’ which is consistent with one’s values, noticing the thoughts and feelings that occur 
in the context of values activity.
Module 3: take an 
observer perspective
 ► Experimenting with taking an observer perspective on one’s experiences.
 ► Considering labels one attaches to oneself (especially given the context of MD). Noticing a choice 
over buying into labels and the impact of labels over one’s behaviour.
 ► Introducing a more flexible approach to mindfulness
 ► Homework 1: continuation of daily mindfulness practice with addition of flexible attention and 
noticing the observer self
 ► Homework 2: continuation of valued activities
Module 4: recap, 
reflection and 
suggestions for staying 
committed
 ► Review of homework tasks and skills learnt.
 ► Self-identification of effective and ineffective behaviour patterns.
 ► Goal planning and normalisation of set-backs with a compassionate approach to getting back on 
track.
ACT, Acceptance and Commitment Therapy; MD, muscle disease.
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(RA) and objective assessments with a physiotherapist. 
Participants will also complete a participant details form 
to provide demographic data as follows: age, gender, 
ethnicity, occupation status, education level, marital 
status, living arrangements and dependants. Clinical 
information will also be collected, including age of onset 
and duration of MD, additional diagnoses, experience 
of psychological therapies as well as prior treatment of 
anxiety or depression. Adverse events will be recorded at 
each assessment point of the trial.
The objective assessments conducted by physiothera-
pists at baseline are as follows:
 ► Adult Ambulatory Neuromuscular Assessment (ANA) 
is an adult version of the North Star Ambulatory 
Assessment33 that measures motor function. Items 
are scored from 0 to 2, with an overall possible range 
of scores from 0 to 34. The higher the score, the 
better the patient can function. An additional item 
of the ANA that shall be used is the 6-minute timed 
walk test which measures mobility by counting the 
distance walked within a 6-minute time-frame along 
with pauses or stops before the time is complete. 
The higher the score, the greater the function of the 
patient.
 ► Manual Muscle Strength Testing (aka Manual Muscle 
Testing) measures the strength of 12 different muscles 
on both right and left from 0 to 5 (no contraction 
palpable–normal strength). There is a total possible 
range of scores from 0 to 120, with higher scores 
representing levels of strength closest to normal 
levels.34
outcome measures
The RA blind to participant allocation will be responsible 
for ensuring outcome measures are completed at 3, 6 
and 9 weeks by all participants. The link to the measures 
will be sent to participants via email. If participants do 
not complete the questionnaires by the due date, they 
will be reminded by the RA. All time points will be taken 
into account during analysis, but the primary efficacy 
endpoint is the 9-week follow-up.
Table 2 Screening and data collection across the trial: summary of key trial processes
Process Screening Baseline 3 weeks 6 weeks 9 weeks
Ongoing 
or during 
trial Ref
Eligibility X –
Medical confirmation X – 
HADS X X X X X 37
MoCA X 28
Participant details form X – 
INQoL X X X X 33
WSAS X X X X 34
HAQ-DI X X X X 37
IBM-FRS X X X X 38
AAQ-II X X X X 40
MASS X X X X 41
CAQ X X X X 42
Health events X X X X – 
ANA X 31
6MTWT X 31
MMST X 32
PGIC X X X 39
Satisfaction rating X X X – 
Safety events (eg, AE, SAEs) X – 
Drop-out/withdrawal X – 
Therapist ratings X – 
AAQ-II, Acceptance and Action Questionnaire; AE, adverse event; ANA, Adult Ambulatory Neuromuscular Assessment; CAQ, Committed 
Action Questionnaire; HADS, Hospital Anxiety and Depression Scale; HAQ-DI, Stanford Health Assessment Questionnaire Disability Index; 
IBM-FRS, inclusion body myositis functional rating scale; INQoL, Individualised Neuromuscular Quality of Life Questionnaire; MAAS, 
Mindfulness Attention Awareness Scale; MMST, Manual Muscle Strength Testing; MoCA, Montreal Cognitive Assessment 5-minute protocol; 
PGIC, Patient Global Impression of Change Scale; SAE, serious adverse event; WSAS, Work and Social Adjustment Scale; 6MTWT, 6-minute 
timed walk test. 
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Primary outcome
 ► The Individualised Neuromuscular Quality of 
Life Questionnaire (INQoL)—life area domains 
(section 2) is the primary outcome. The INQoL is 
a 10-domain, validated MD-specific questionnaire 
to measure QoL.35 We will exclude the one domain 
that addresses the symptom of myotonia as none of 
the MDs being recruited has this symptom. This will 
leave nine domains for the purpose of this study. The 
primary outcome of this study constitutes section 2 of 
the INQoL which assesses five life area domains (activ-
ities, independence, social functioning, emotional 
functioning and body image). Participants respond 
using a seven-point Likert scale, with higher scores 
indicating greater symptom impact. The primary 
outcome measure for this study will therefore be the 
change in the overall QoL score, derived from these 
five life domain scores, from baseline up to 9 weeks.
Secondary outcome measures
 ► INQoL symptom impact domains. This refers to 
categories within section 1 of the INQoL (weakness, 
pain and tiredness) and follows the same format as 
described above.
 ► Work and Social Adjustment Scale (WSAS) is a 
measure of impairment at work, home and social 
functioning.36 The total score comprises the sum 
of responses to five questions, each of which is on a 
nine-point Likert scale. The possible range of scores 
is 0–40; with higher scores indicating more greatly 
impaired daily functioning.
 ► HADS is a self-report questionnaire to measure 
mood.37 It consists of 14 items, relating to depression 
(seven items) and anxiety (seven items). Higher scores 
indicate either greater anxiety or depression. Each of 
the items is rated from 0 to 3; thus, the possible range 
of scores for each is 0–21, with a cut-off of 8 showing 
good sensitivity and specificity for possible cases.38
 ► Stanford Health Assessment Questionnaire Disability 
Index (HAQ-DI) is a measure of functional impair-
ment and level of disability.39 There are different 
ways to score the HAQ-DI. As with previous studies 
with MD populations,18 the alternative scoring 
method shall be used which focuses on measuring 
disability not adaption by not incorporating use of 
aids and devices. The measure includes eight activity 
domains (dressing, arising, eating, walking, hygiene, 
reach, grip and activities). There are 20 questions in 
total, each scored from 0 to 3. All the domains are 
summed for a total score with a higher score repre-
senting a greater impairment in ability to function 
in daily life. As an additional measure of functional 
impairment, not treated as an efficacy outcome in 
the analysis, the IBM Functional Rating Scale40 will 
be completed only by those participants with a diag-
nosis of IBM. This is a 10-point functional rating 
scale, with higher scores depicting greater func-
tional impairment.
 ► Patient Global Impression of Change Scale (PGIC) 
is a single-item measure of a patient’s impression of 
change over the study.41 Participants rate their impres-
sion of change on a scale of 1–7 as follows: ‘very much 
better’, ‘much better’, ‘a little better’, ‘about the 
same’, ‘a little worse’, ‘much worse’ and ‘very much 
worse’.
 ► Rating of satisfaction is a single-item measure of a 
patient’s satisfaction with the outcome of the trial. 
Participants rate their satisfaction on a scale of 1–7 as 
follows: ‘very satisfied’, ‘moderately satisfied’, ‘slightly 
satisfied’, ‘neither’, ‘slightly dissatisfied’, ‘moderately 
dissatisfied’ and ‘very dissatisfied’.
Putative mediators and process variables
 ► Acceptance and Action Questionnaire (AAQ-II)42 
measures psychological flexibility, including experi-
ential avoidance and psychological inflexibility. Each 
of the seven items are rated on a scale of 1–7, with 
higher scores representing greater experiential avoid-
ance and immobility.
 ► Mindfulness Attention Awareness Scale (MAAS) 
measures dispositional open awareness of and atten-
tion to the present moment.43 There are 15 items, 
each scored from 1 to 6. A mean of the 15 items is 
computed, with higher scores reflecting higher levels 
of dispositional mindfulness.
 ► Committed Action Questionnaire (CAQ) measures 
committed action, that is, goal-directed, flexible 
persistence.44 Respondents rate the extent to which 
the eight items apply to them from 0 to 6 with a greater 
total score representing a greater general propensity 
to persist in goal-directed behaviour.
Qualitative component
A nested qualitative study will explore patients’ expe-
rience of the ACT intervention. This will help identify 
factors that facilitate or impede adherence and accept-
ability of the treatment and perhaps give insight into 
treatment mechanisms. Semi-structured interviews will 
be conducted post-intervention with approximately 15 
participants (purposively sampled to encompass a mix 
of gender, ages and symptom severity). Interviewers will 
use topic guides with open-ended questions and prompts 
to elicit participants’ accounts of their experiences. The 
interviews will be transcribed verbatim. Analysis will 
commence after the completion of the first interview in 
an iterative process to allow exploration of early insights 
in later interviews. Standard thematic analysis techniques 
will be applied,45 for example, coding the data and iden-
tifying themes that capture key concepts and processes. 
The results will supplement quantitative results and 
inform any future implementation of the intervention.
Participant timeline
Information is provided in the consort diagram (figure 1) 
and the screening and data schedule of assessments 
(table 2). The RA will contact potentially interested 
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participants to ensure that they are fully informed and 
eligible to take part in the trial. If this is the case, they will 
be asked to sign a consent form, enrolled onto the study 
and provided with a unique identification number. The 
baseline assessments will be in person at one of the MD 
clinics with the RA and physiotherapist. Following base-
line, the participant will be randomised and informed by 
the trial coordinator as to whether they will receive ACT 
plus SMC or SMC alone. The participant will complete 
follow-up measures at 3, 6 and 9 weeks online via an email 
link.
sample size
One hundred and fifty-four patients will be recruited 
in total, 77 per trial arm. This sample size will provide 
adequate power to detect a standardised mean difference 
of 0.5 (medium magnitude) in the primary outcome 
between the treatment and control groups at the end of 
intervention assessment (5% significance, 80% power), 
assuming attrition of 20%. Using data from Vincent 
et al,35 this equates to between an 11.5-point and 15.8-
point difference on each of the INQoL domains. While 
no information is currently available regarding clinically 
important differences for the INQoL, an effect size of this 
magnitude typically relates to a clinically important differ-
ence for health-related QoL instruments.46
recruitment
Participants will be recruited from MD clinics, MD-UK and 
MD registries. In MD clinics, consultants and physiothera-
pists will identify potentially eligible participants who will 
either be given an information pack consisting of an invi-
tation letter, information sheet and reply slip to state their 
interest. MD-UK and MD registries will advertise the study 
and provide invitation packs. When someone states their 
interest, the RA will call them to provide further informa-
tion, answer any questions and conduct screening. If they 
are eligible for the study (including medical confirmation 
from their health professional), then the participant will 
sign a consent form before being enrolled into the study.
Patient and public involvement
MR’s direct work with patients within an MD clinic led 
to the development of the trial. In developing the study 
material, a small pilot study of the self-guided interven-
tion was tested and subsequently refined in response 
to participants’ feedback by CG (Graham, 2012). Our 
patient representative has been actively involved at every 
Figure 1 Consort diagram for ACTMus. ACT, Acceptance and Commitment Therapy; ACTMus, Acceptance and Commitment 
Therapy for Muscle Disease; MD, muscle disease; SMC, standard medical care.
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stage from assessing the intervention to reviewing the 
outcome measures. MD-UK, a patient support organisa-
tion, contributed to the development of the study and will 
help with the referral of patients into the study. MD-UK 
will also be involved in disseminating study results.
MEthods: AssIgnMEnt of IntErvEntIons
Allocation
Randomisation will be conducted by an independent 
randomisation service at the UK Clinical Research 
Collaboration registered at the King’s Clinical Trials Unit. 
Randomisation will be at the level of the individual, using 
block randomisation with randomly varying block sizes 
stratified by recruiting centre. Allocation confirmation 
will be generated automatically and sent to unblinded 
research members, including the trial coordinator and 
clinical psychologist.
Allocation concealment
A position of equipoise will be maintained, but blinding 
of the patients and therapist to the treatment condition 
will not be possible. The RA contacting participants and 
inputting data will be blind to group allocation to reduce 
the risk of introducing bias. To protect against unblinding, 
all follow-up questionnaires will be completed by partici-
pants on Bristol Online Survey (BOS) which is specifically 
designed for academic research and fully compliant with 
UK data protection law. All questionnaires will be iden-
tical for both arms and designed not to reveal treatment 
allocation. The trial statistician will be blind to treatment 
group when conducting the main data analysis.
MEthods: dAtA CollECtIon, MAnAgEMEnt And AnAlysIs
data collection methods
Baseline data will be collected prior to randomisation and 
consist of self-report questionnaires and objective assess-
ments with the physiotherapist. Follow-up data (3, 6 and 
9 weeks) include self-report questionnaires that will be 
completed remotely. At each follow-up point, participants 
will be emailed a link to BOS along with their unique iden-
tification number. If participants are unwilling or unable 
to complete all the questionnaires, they will be given the 
option of going through them on the phone or a reduced 
questionnaires pack with the primary outcomes (INQoL).
data management
All trial data will be stored in line with the Data Protection 
Act 1998 and in compliance with Good Clinical Practice 
and King’s College London data management proce-
dures. Any identifying data will be anonymised through 
use of unique identification numbers separated from 
identifying data. Data will be entered onto password-pro-
tected trial databases either on a shared hard-drive 
accessible only to assigned team members or in a locked 
cabinet in a room only accessible to staff with designated 
access cards. All source documents will be retained for a 
period of 10 years following the end of the study.
statistical methods
Statistical analyses of the primary and secondary outcomes 
will be conducted after the database has been locked, with 
no interim analyses. All analyses will adopt the intention 
to treat principle. The main statistical analyses will esti-
mate the difference in mean outcomes between patients 
randomised to ACT plus SMC and SMC alone at the 
primary endpoint of 9 weeks and at the two other postran-
domisation time points. Group difference estimates, asso-
ciated CIs and standardised effect sizes will be reported. 
Significance testing will be performed where the signifi-
cance level will be 5% (two-sided). Sensitivity analyses will 
be used to assess the robustness of conclusions to missing 
outcome data using a pattern mixture model approach 
and to departures from randomised treatment in a per 
protocol analysis excluding those not receiving. Loss to 
follow-up, departures from randomised treatment and 
the prevalence of serious adverse events (SAEs) will be 
reported.
The primary outcome is the INQoL QoL score. Quality 
of life at all three postrandomisation time points (3, 6 
and 9 weeks after randomisation) will be modelled simul-
taneously using a linear mixed-effects model. A random 
intercept will account for the non-independence of obser-
vations across individuals. Trial arm and indicator-coded 
time will be included as covariates along with arm by time 
interaction terms to allow the treatment effect to vary at 
each time point. In addition, included in the model will 
be the baseline level of the QoL score and a stratification 
indicator variable for centre. Missing data at follow-up 
assessments are allowed where at least one observation 
per participant is available under the missing at random 
assumption.
Secondary patient outcomes (3, 6 and 9 weeks after 
randomisation) relating to symptom severity and func-
tioning (WSAS and HAQ-DI), distress (HADS), impres-
sion of change (PGIC) and putative mediators of the 
intervention (CAQ, AAQ-II and MAAS) will be analysed 
using linear mixed-effects models. Random effects for the 
intercept and time will be included in the model.
MEthods: MonItorIng
data monitoring
The study will be monitored and audited in accordance 
with King’s College Hospital NHS Foundation Trust 
and King’s College London procedures. All trial related 
documentation will be made available on request to the 
sponsors, Health Research Authority/Research Ethics 
Committee (REC) and other licensing bodies. Moni-
toring of this study to ensure compliance with Good 
Clinical Practice and scientific integrity will be managed 
by the study team and reviewed by an independent Trial 
Steering Committee (TSC) and Data Monitoring & Ethics 
Committee (DMEC).
harms/assessment of safety
Adverse events will be recorded at baseline, 3, 6 and 9 
weeks. We define adverse events as “any clinical change, 
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disease or disorder experienced by the participant during 
their participation in the trial, whether or not consid-
ered related to the use of treatments being studied in the 
trial”.47 Adverse events will also include any other events 
that might have affected the health status of a partici-
pating patient (eg, increased work stress).
The team will also monitor SAEs, serious adverse reac-
tions (SAR), suspected unexpected serious adverse reac-
tions (SUSAR) and active withdrawals from treatment. An 
SAE constitutes any adverse event or reaction that: results 
in death or a new persistent or new significant disability 
or incapacity, is life threatening or requires hospitalisa-
tion, any new episode of deliberate self-harm or any other 
important medical condition which may jeopardise the 
participant and requires medical or surgical intervention 
to prevent one of the outcomes listed above.
An SAR can be defined as an SAE as a reaction to the 
intervention. An SUSAR is any SAR that is suspected to 
be caused by the intervention but was not expected. All 
SAEs, SARs and SUSARs will be reported immediately by 
the chief investigator to the study sponsor and REC. The 
TSC-DMEC will be responsible for the independent inves-
tigation of SAEs.
research ethics approval
Site-specific confirmation of capacity and capability has 
been given by local research and development depart-
ments. The study will comply with the principles of the 
Declaration of Helsinki (1996),48 the International 
Conference for Harmonisation of Good Clinical Prac-
tice49 guidelines and the Research Governance Frame-
work for Health and Social Care Second Edition (2005). 
The trial is sponsored by King’s College Hospital NHS 
Foundation Trust (lead) and King’s College London and 
has been registered onto a publicly accessible database 
(registration no NCT02810028).
Consent
Inclusion in the trial is appropriate only if potential 
participants are aged 18 years or older and are able to 
give written informed consent. All potentially eligible 
participants will be fully informed about the study proce-
dures by a participant information sheet that states partic-
ipation is voluntary, and that they are free to withdraw 
from the study at any time without giving a reason and 
without their care being affected.
declaration of interests
The authors declare that they have no competing 
interests.
dissemination
Summaries of findings will be offered to MD charities, 
registries and support groups as well as to the wider 
public. The results of the trial will be communicated to 
participants via a newsletter. Any results from the trial 
will enable informed decisions regarding the provision of 
care for patients with MD.
ConClusIon
Experiences of psychological distress and reduced QoL 
are common in people with MD. A brief, guided self-help 
ACT intervention with telephone support sessions has 
been designed for remote delivery, offering a potential 
solution to mobility issues inherent with MD and under-re-
sourced healthcare services. This is the first study to eval-
uate whether ACT can help improve QoL for individuals 
with MD. It will also be one of the largest RCTs of ACT 
for improving outcomes in chronic diseases/long-term 
conditions. If the intervention proves to be efficacious, 
this treatment delivery could facilitate participation for 
those individuals whose impaired mobility prevents trav-
elling to face-to-face sessions. As the main barrier to the 
adoption of any psychological intervention is the paucity 
of psychological services, the ACT intervention has 
been designed to be a self-guided programme requiring 
minimal support from highly qualified professionals.
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